ZTS Zoetis Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1555280 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.0%
TTM net income YoY-5.5%
TTM EPS YoY0.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR2.9%
Margins
Gross margin71.4%
Operating margin—
Net margin26.1%
FCF margin24.0%
EBITDA margin—
Returns
ROE57.1%
ROA16.4%
ROIC (approx.)—
Asset turnover0.63x
Leverage & solvency
Liabilities / assets78.1%
Debt / equity2.74x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.39B | $2.47B | $2.26B | $2.39B | $2.42B | $2.47B | $2.20B | $2.32B |
| Cost of revenue | $698.00M | $673.00M | $641.00M | $712.00M | $697.00M | $664.00M | $618.00M | $707.00M |
| Gross profit | $1.69B | $1.79B | $1.62B | $1.68B | $1.73B | $1.81B | $1.58B | $1.61B |
| R&D expense | $174.00M | $173.00M | $180.00M | $199.00M | $175.00M | $166.00M | $162.00M | $186.00M |
| SG&A expense | $582.00M | $592.00M | $588.00M | $619.00M | $582.00M | $614.00M | $574.00M | $625.00M |
| Interest expense | $62.00M | $61.00M | $62.00M | $57.00M | $58.00M | $53.00M | $54.00M | $51.00M |
| Pretax income | $729.00M | $866.00M | $758.00M | $761.00M | $886.00M | $912.00M | $773.00M | $732.00M |
| Income tax | $138.00M | $175.00M | $157.00M | $158.00M | $165.00M | $186.00M | $171.00M | $151.00M |
| Net income | $591.00M | $691.00M | $601.00M | $603.00M | $721.00M | $726.00M | $602.00M | $581.00M |
| EPS (basic) | 1.44 | 1.65 | 1.42 | — | 1.63 | 1.63 | 1.34 | — |
| EPS (diluted) | 1.44 | 1.65 | 1.42 | — | 1.63 | 1.63 | 1.34 | — |
| Dividends declared per share | 0.00 | 0.53 | 0.53 | 1.03 | 0.00 | 0.50 | 0.50 | 0.93 |
| Weighted avg. shares (diluted) | 411.60M | 417.70M | 422.40M | — | 443.20M | 445.50M | 448.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.33B | $1.48B | $1.94B | $2.45B | $2.27B | $1.63B | $1.78B | $2.11B |
| Short-term investments | $200.00M | $200.00M | — | $0 | — | — | — | — |
| Receivables | $1.69B | $1.57B | $1.51B | $1.41B | $1.54B | $1.54B | $1.36B | $1.32B |
| Inventory | $2.54B | $2.57B | $2.55B | $2.46B | $2.46B | $2.44B | $2.37B | $2.31B |
| Current assets | $6.29B | $6.36B | $6.47B | $6.77B | $6.58B | $5.92B | $5.88B | $5.99B |
| PP&E, net | $3.78B | $3.76B | $3.72B | $3.69B | $3.60B | $3.54B | $3.44B | $3.39B |
| Goodwill | $2.89B | $2.77B | $2.78B | $2.77B | $2.76B | $2.76B | $2.72B | $2.72B |
| Intangibles | $850.00M | $918.00M | $959.00M | $998.00M | $1.04B | $1.07B | $1.08B | $1.13B |
| Total assets | $15.09B | $15.08B | $15.15B | $15.49B | $15.16B | $14.48B | $14.10B | $14.24B |
| Current liabilities | $2.68B | $2.06B | $2.05B | $2.17B | $1.81B | $3.37B | $3.38B | $3.41B |
| Short-term debt | $750.00M | — | — | $0 | $0 | $1.35B | $1.35B | $1.35B |
| Long-term debt | $8.30B | $9.05B | $9.04B | $9.04B | $7.07B | $5.23B | $5.23B | $5.22B |
| Total debt | $9.05B | $9.05B | $9.04B | $9.04B | $7.07B | $6.58B | $6.58B | $6.57B |
| Total liabilities | $11.79B | $11.93B | $11.92B | $12.07B | $9.76B | $9.50B | $9.44B | $9.47B |
| Shareholders' equity | $3.30B | $3.15B | $3.23B | $3.42B | $5.40B | $4.98B | $4.66B | $4.77B |
| Net debt | $7.72B | $7.57B | $7.10B | $6.59B | $4.80B | $4.95B | $4.79B | $4.46B |
| Shares outstanding | 407.49M | 414.15M | 420.35M | 424.93M | 441.46M | 443.95M | 446.04M | 448.47M |
| Cash flow statement | ||||||||
| Operating cash flow | $824.00M | $655.00M | $401.00M | $893.00M | $936.00M | $605.00M | $515.00M | $905.00M |
| Capital expenditure | $107.00M | $117.00M | $110.00M | $161.00M | $138.00M | $146.00M | $178.00M | $216.00M |
| Free cash flow | $717.00M | $538.00M | $291.00M | $732.00M | $798.00M | $459.00M | $337.00M | $689.00M |
| Investing cash flow | -$262.00M | -$300.00M | -$87.00M | -$166.00M | -$168.00M | -$212.00M | -$203.00M | $126.00M |
| Financing cash flow | -$718.00M | -$813.00M | -$840.00M | -$495.00M | -$134.00M | -$564.00M | -$677.00M | -$745.00M |
| Depreciation & amortization | $119.00M | $119.00M | $119.00M | $122.00M | $122.00M | $124.00M | $119.00M | $123.00M |
| Stock-based compensation | $27.00M | $26.00M | $25.00M | $22.00M | $22.00M | $22.00M | $17.00M | $19.00M |
| Share buybacks | $500.00M | $584.00M | $1.53B | $2.06B | $394.00M | $338.00M | $443.00M | $553.00M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.